Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 11, 2026, 7:49 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 398 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: hemoglobin A1c Clear all

Conditions: Type 1 Diabetes Mellitus
Interventions: cinnamon; Drug
Lead sponsor: Dartmouth-Hitchcock Medical Center; Other
Eligibility: 13 Years to 18 Years
Enrollment: 72 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2006
U.S. locations: 1
States / cities: Lebanon, New Hampshire

Conditions: Weight Loss, Blood Pressure, Lipid Disorder, PreDiabetes, Diabete Mellitus
Interventions: Low-fat plant-based diet; Behavioral
Lead sponsor: Physicians Committee for Responsible Medicine; Other
Eligibility: 18 Years and older
Enrollment: 48 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: Washington D.C., District of Columbia

Conditions: Diabetes Mellitus, Type 2
Interventions: Produce prescription (weekly produce delivery); Other
Lead sponsor: Kaiser Permanente; Other
Eligibility: 18 Years to 70 Years
Enrollment: 460 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 1
States / cities: Pasadena, California

Conditions: Partially Edentulous Mandible, Type 2 Diabetes
Interventions: dental implant and modified dental implant; Device
Lead sponsor: The University of Texas Health Science Center at San Antonio; Other
Eligibility: 18 Years and older
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2012
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Prediabetic State
Interventions: GlucoSupreme™ Herbal, Placebo; Dietary Supplement · Other
Lead sponsor: University of Maryland, Baltimore; Other
Eligibility: 18 Years and older
Enrollment: 39 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2020
U.S. locations: 4
States / cities: Baltimore, Maryland • Cincinnati, Ohio

Conditions: Diabetes Mellitus, Type 2
Interventions: exenatide; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 456 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2006
U.S. locations: 60
States / cities: Birmingham, Alabama • Anaheim, California • Bellflower, California + 57 more

Conditions: Diabetes Mellitus, Type 1
Interventions: Not listed
Lead sponsor: Yale University; Other
Eligibility: 18 Years to 55 Years
Enrollment: 36 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2011
U.S. locations: 2
States / cities: New Haven, Connecticut • Minneapolis, Minnesota

Conditions: Diabetes, Diabetes Mellitus, Type 2
Interventions: liraglutide, glimepiride, placebo; Drug
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 746 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2008
U.S. locations: 102
States / cities: Concord, California • Escondido, California • Fullerton, California + 83 more

Conditions: Diabetes Mellitus, Type 2
Interventions: AC2993, Placebo; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 16 Years to 75 Years
Enrollment: 336 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2003
U.S. locations: 129
States / cities: Anniston, Alabama • Birmingham, Alabama • Eclectic, Alabama + 99 more

Conditions: Osteoarthritis, Knee, Osteoarthritis, Hip, Avascular Necrosis, Rheumatoid Arthritis
Interventions: POPOP (preoperative patient optimization program), SOC (standard of care); Other
Lead sponsor: University of Arkansas; Other
Eligibility: 18 Years to 80 Years
Enrollment: 46 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 1
States / cities: Little Rock, Arkansas

Conditions: Diabetes Mellitus, Type 2
Interventions: Canagliflozin 100 mg, Canagliflozin 300 mg, Antihyperglycemic agent(s), Placebo; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 55 Years to 80 Years
Enrollment: 716 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2013
U.S. locations: 34
States / cities: Glendale, Arizona • Phoenix, Arizona • Little Rock, Arkansas + 31 more

Conditions: Diabetes Mellitus, Type 2
Interventions: Not listed
Lead sponsor: Sashwati Roy; Other
Eligibility: 40 Years to 60 Years
Enrollment: 42 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2018
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Type 1 Diabetes, Hypoglycemia, High Blood Sugar
Interventions: Dexcom G6 Continuous Glucose Monitor; Device
Lead sponsor: Johns Hopkins University; Other
Eligibility: 5 Years to 21 Years
Enrollment: 26 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Type 2 Diabetes Mellitus (T2D)
Interventions: Food Bundle Intervention; Other
Lead sponsor: Wake Forest University Health Sciences; Other
Eligibility: 18 Years and older
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Winston-Salem, North Carolina

Conditions: Diabetes Mellitus
Interventions: "Diabetes Report Card"; Other
Lead sponsor: University of Pennsylvania; Other
Eligibility: 18 Years and older
Enrollment: 177 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Type 2 Diabetes
Interventions: Acceptance Based Coping (ABaCo) Skills Program; Behavioral
Lead sponsor: Baylor College of Medicine; Other
Eligibility: 18 Years to 70 Years
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Diabetes Mellitus, Type 2, Obesity
Interventions: canagliflozin, Placebo (for canagliflozin); Drug
Lead sponsor: The Cleveland Clinic; Other
Eligibility: 20 Years to 75 Years
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Type 2 Diabetes Mellitus, Hyperglycemia
Interventions: Diabetes Pathway; Other
Lead sponsor: Medstar Health Research Institute; Other
Eligibility: 21 Years to 75 Years
Enrollment: 419 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 1
States / cities: Washington D.C., District of Columbia

Conditions: Type 2 Diabetes
Interventions: SMBG to guide clinical decisions, SMBG and CGM; Other
Lead sponsor: HealthPartners Institute; Other
Eligibility: 18 Years to 75 Years
Enrollment: 91 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: HIV, Diabetes, Hyperglycemia
Interventions: Not listed
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years and older
Enrollment: 175 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2007
U.S. locations: 2
States / cities: Washington D.C., District of Columbia • Bethesda, Maryland

Conditions: Obesity, Insulin Resistance, Metabolically Healthy Obesity, Obesity, Metabolically Benign
Interventions: People with Metabolically Unhealthy Obesity - Low Calorie Diet; Behavioral
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 25 Years to 55 Years
Enrollment: 72 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2028
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Diabetes, Diabetes Mellitus, Type 2
Interventions: pioglitazone, inhaled human insulin; Drug
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: 18 Years and older
Enrollment: 196 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2008
U.S. locations: 110
States / cities: Ozark, Alabama • Tuscaloosa, Alabama • Vestavia Hills, Alabama + 100 more

Conditions: Diabetes Mellitus, Type 2
Interventions: GSK189075, Placebo; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 250 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 65
States / cities: Mesa, Arizona • Artesia, California • Buena Park, California + 54 more

Conditions: Type2 Diabetes, Type 2 Diabetes Mellitus in Obese, Dysglycemia, Microvascular Complications, Brain Structure, Obesity, Childhood, Diabetes in Adolescence, Inflammation, Insulin Resistance, Overweight, Childhood, Cognitive Decline
Interventions: Observational; Other
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 12 Years to 17 Years
Enrollment: 117 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2027
U.S. locations: 2
States / cities: St Louis, Missouri • Pittsburgh, Pennsylvania

Search by objective public record fields.

The Effect of Cinnamon on HbA1c Among Adolescents With Type I Diabetes

Feasibility & Implementation of a Plant-Based Weight-Loss Program in an Office-Based Setting

Food As Medicine Study

Comparative Study of Implant Surfaces to Enhance Stabilization in Patients With Type 2 Diabetes

RCT of a Polyherbal Dietary Supplement for Prediabetes

Study to Examine the Effect on Glucose Control and Safety/Tolerability of Exenatide Given Two Times a Day to Subjects With Type 2 Diabetes

The Impact of Pancreatic Islet Cell Allotransplantation on Cognitive Function in Type 1 Diabetes Mellitus

To Evaluate the Effect of Liraglutide Versus Glimepiride (Amaryl®) on Haemoglobin A1c

Evaluation of the Effect on Glucose Control of AC2993 in Patients With Type 2 Diabetes Mellitus Treated With Metformin

Impact of a POPOP on Preoperative Health, Eligibility, and Clinical & Patient-Reported Outcomes in TJA

A Safety and Efficacy Study of Canagliflozin in Older Patients (55 to 80 Years of Age) With Type 2 Diabetes Mellitus

Leukocyte Dysfunction in Diabetic Patients.

CGM Use in Poorly Controlled Youth With Type 1 Diabetes

Culturally Tailored Program for Food-Insecure Adults: SPICE-D

New Ways to Help Patients Improve Their Diabetes Control

SALUD-M: Acceptance Based Coping Skills for Hispanic/Latinx Military Patients With Type 2 Diabetes

CARAT: Canagliflozin vs. Placebo for Post Bariatric Patients With Persistent Type 2 Diabetes

MedStar Health Type 2 Diabetes Pathway to Control

Modal Day Analysis of Self Monitoring Blood Glucose Versus Continuous Glucose Monitoring

Accuracy of Hemoglobin A1C to Predict Glycemia in HIV

Small Extracellular Vesicles and Insulin Action

Effect of Inhaled Insulin (AERx® iDMS) on Blood Glucose Control in Type 2 Diabetes

Dose-Ranging Study In Subjects With Type 2 Diabetes Mellitus Who Are Treatment-Naive

Brain Health in Youth With Normal Weight, Overweight and Obesity at Risk for Type 2 Diabetes (T2D)